Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-mesothelin antibody-drug conjugate BMS-986148

An antibody-drug conjugate (ADC) composed of a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface glycoprotein and tumor-associated antigen (TAA) mesothelin and conjugated, via a valine-citrulline linker, to the cytotoxic agent tubulysin, with potential antineoplastic activity. Upon administration of anti-mesothelin ADC BMS-986148, the monoclonal antibody moiety targets and binds to mesothelin. Upon internalization, the tubulysin moiety inhibits the polymerization of tubulin into microtubules. This leads to cell cycle arrest, induces tumor cell apoptosis, and may inhibit cellular proliferation of mesothelin-expressing tumor cells. Mesothelin is overexpressed by all mesotheliomas and a variety of other cancers, while it is minimally expressed in normal tissue.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:BMS-986148
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search